Clinical Observation on <italic style="font-style: italic">Tianmeng Lingjiao Formula</italic>（天礞羚角方） as an Adjunctive Therapy for Paroxysmal Atrial Fibrillation with Phlegm-Heat Harassing the Interior Syndrome

CHEN Jiafan; DUAN Chenglin; DU Yihang; QI Lianfen; SHAN Xinjue; LI Jiaqi; ZHANG Wenjing; CHENG Tao; JIA Bochao; CHEN Zizhen; SHI Jingjing; CHU Yuguang; SUN Yuwen; HU Yuanhui

doi:10.13288/j.11-2166/r.2026.20.009

您当前的位置：

首页 >

文章列表页 >

Clinical Observation on Tianmeng Lingjiao Formula（天礞羚角方） as an Adjunctive Therapy for Paroxysmal Atrial Fibrillation with Phlegm-Heat Harassing the Interior Syndrome

更新时间：2026-10-10

- Clinical Observation on Tianmeng Lingjiao Formula（天礞羚角方） as an Adjunctive Therapy for Paroxysmal Atrial Fibrillation with Phlegm-Heat Harassing the Interior Syndrome
- Journal of Traditional Chinese Medicine Vol. 67, Issue 20, Pages: 2195-2201(2026)
- 作者机构：
  
  1.中国中医科学院广安门医院，北京市西城区北线阁5号，100053
  2.北京中医药大学
  3.解放军总医院第一医学中心
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2026.20.009
  CLC：
- Received：11 March 2026，
  
  Revised：2026-07-30，
  
  Accepted：20 July 2026，
  
  Published：17 October 2026
- 稿件说明：
移动端阅览
陈佳凡,段城林,杜宜航等.天礞羚角方辅助治疗痰热内扰证阵发性房颤54例临床观察[J].中医杂志,2026,67(20):2195-2201.

CHEN Jiafan,DUAN Chenglin,DU Yihang,et al.Clinical Observation on Tianmeng Lingjiao Formula（天礞羚角方） as an Adjunctive Therapy for Paroxysmal Atrial Fibrillation with Phlegm-Heat Harassing the Interior Syndrome[J].Journal of Traditional Chinese Medicine,2026,67(20):2195-2201.
陈佳凡,段城林,杜宜航等.天礞羚角方辅助治疗痰热内扰证阵发性房颤54例临床观察[J].中医杂志,2026,67(20):2195-2201. DOI： 10.13288/j.11-2166/r.2026.20.009.

CHEN Jiafan,DUAN Chenglin,DU Yihang,et al.Clinical Observation on Tianmeng Lingjiao Formula（天礞羚角方） as an Adjunctive Therapy for Paroxysmal Atrial Fibrillation with Phlegm-Heat Harassing the Interior Syndrome[J].Journal of Traditional Chinese Medicine,2026,67(20):2195-2201. DOI： 10.13288/j.11-2166/r.2026.20.009.

摘要

目的

观察天礞羚角方辅助治疗痰热内扰证阵发性房颤的临床疗效及安全性。

方法

收集痰热内扰证阵发性房颤患者90例，按照治疗组与对照组2∶1比例随机分为治疗组60例和对照组30例。对照组给予西医常规治疗，治疗组在此基础上加用天礞羚角方，每日1剂，两组疗程均为4周。比较两组患者治疗后中医证候疗效和房颤转复率，评估治疗前后房颤负荷、每月房颤发作次数及持续时间、中医证候积分、欧洲心律协会（EHRA）房颤症状分级情况，并检测血、尿、便常规及肝肾功能、电解质水平，记录不良事件发生情况，评价安全性。

结果

共82例患者完成研究，其中治疗组54例、对照组28例。治疗后两组患者房颤负荷、中医证候积分、每月房颤发作次数、每月房颤持续时间均较治疗前降低，且治疗组治疗后均低于对照组（

＜0.05或

＜0.01）。治疗组房颤转复率为25.93%（14/54），显著高于对照组的3.57%（1/28，

＜0.05）。治疗组中医证候疗效总有效率为83.33%（45/54），显著高于对照组的67.86%（19/28，

＜0.05）。治疗后治疗组EHRA房颤症状分级情况较治疗前明显好转，且治疗组EHRA房颤症状分级情况优于对照组（

＜0.05或

＜0.01）。两组治疗过程中均未发生不良事件，安全性指标未见明显异常。

结论

天礞羚角方辅助治疗可降低痰热内扰证阵发性房颤患者房颤负荷，提高房颤转复率，减少每月房颤发作次数及持续时间，改善患者中医症状，且安全性良好。

Abstract

Objective

To observe the clinical efficacy and safety of

Tianmeng Lingjiao Formula

（天礞羚角方， TLF） as an adjunctive therapy for paroxysmal atrial fibrillation （PAF） with phlegm-heat harassing the interior syndrome.

Methods

Ninety patients with PAF and phlegm-heat harassing the interior syndrome were enrolled and randomly assigned in a 2∶1 ratio to test group （60 cases） and control group （30 cases）. The control group received conventional western medicine， while the test group received TLF in addition to the conventional treatment， with one dose administered daily. The treatment course for both groups was 4 weeks. The efficacy of traditional Chinese medicine （TCM） syndrome and the rate of atrial fibrillation （AF） conversion were compared between groups. Assessments included AF burden， frequency and duration of AF episodes， TCM syndrome scores， and European Heart Rhythm Association （EHRA） AF symptom classification before and after treatment. Safety indicators such as blood routine， urine routine， stool routine， liver function， kidney function， and electrolytes were also monitored. Adverse events were recorded.

Results

A total of 82 patients completed the study （54 in the test group and 28 in the control group）. After treatment， AF burden， the frequency and duration of AF episodes， and TCM syndrome scores were sig

nificantly reduced in both groups， and the test group showed lower indicators than the control group （

＜0.01 or

＜0.05）. The AF conversion rate was 25.93% （14/54） in the test group， significantly higher than 3.57% （1/28） in the control group （

＜0.05）. The total effective rate for TCM syndrome efficacy was 83.33% （45/54） in the test group， which was significantly higher than 67.86% （19/28） in the control group （

＜0.05）. After treatment， the EHRA atrial fibrillation symptom severity in the test group showed significant improvement， and the improvement in atrial fibrillation symptoms was superior to that in the control group （

＜0.01or

＜0.05）. No significant abnormalities were observed in safety indicators， and no adverse events occurred during the trial.

Conclusion

TLF as an adjunctive therapy can reduce AF burden， enhance the conversion rate of AF， decrease the frequency and duration of episodes， and improve clinical symptoms in patients with paroxysmal atrial fibrillation presenting with phlegm-heat harassing the interior syndrome， with a favorable safety profile.

关键词

Keywords

references

Van Gelder I C ， Rienstra M ， Bunting K V ， et al . 2024 ESC Guidelines for the management of atrial fibrillation deve-loped in collaboration with the European Association for Cardio-Thoracic Surgery （EACTS）［J］. Eur Heart J ， 2024 ， 45 （ 36 ）： 3314 - 3414 .

中华医学会心电生理和起搏分会，中国医师协会心律学专业委员会 . 中国心房颤动管理指南（2025）［J］. 中国心脏起搏与心电生理杂志， 2025 ， 39 （ 4 ）： 273 - 343 .

胡元会，寿鑫甜，朱雪萍，等 . 心房颤动中医药治疗的思考与优势［J］. 北京中医药， 2022 ， 41 （ 10 ）： 1076 - 1078 .

杜宜航，段城林，朱雪萍，等 . 从“脾-脉-心-神”一体观辨治心房颤动［J］. 中医杂志， 2025 ， 66 （ 1 ）： 89 - 92 .

胡元会，吴华芹，褚瑜光，等 . 房颤临证从新［M］. 北京：人民卫生出版社， 2023 ： 66 - 67 .

Joglar J A ， Chung M K ， Armbruster A L ， et al . 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation： a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines ［J/OL］. Circulation ， 2024 ， 149 （ 1 ）： e1 - e156 . https：//pubmed.ncbi.nlm.nih.gov/38033089/ https://pubmed.ncbi.nlm.nih.gov/38033089/ .

中华医学会心血管病学分会，中国生物医学工程学会心律分会 . 心房颤动诊断和治疗中国指南［J］. 中华心血管病杂志， 2023 ， 51 （ 6 ）： 572 - 618 .

中华人民共和国卫生部 . 中药新药临床研究指导原则（第二辑）［M］. 北京：中华人民共和国卫生部， 1995 ： 91 - 94 .

国家中医药管理局医政司 . 24个专业104个病种中医诊疗方案［M］. 北京：中国中医药出版社， 2012 ： 66 - 69 .

Hindricks G ， Potpara T ， Dagres N ， et al . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery （EACTS）： the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology （ESC） developed with the special contribution of the European Heart Rhythm Association （EHRA） of the ESC ［J］. Eur Heart J ， 2021 ， 42 （ 5 ）： 373 - 498 .

Lip G Y ， Nieuwlaat R ， Pisters R ， et al . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach： the Euro heart survey on atrial fibrillation ［J］. Chest ， 2010 ， 137 （ 2 ）： 263 - 272 .

Pisters R ， Lane D A ， Nieuwlaat R ， et al . A novel user-friendly score （HAS-BLED） to assess 1-year risk of major bleeding in patients with atrial fibrillation： the Euro Heart Survey ［J］. Chest ， 2010 ， 138 （ 5 ）： 1093 - 1100 .

Piccini J P ， Dufton C ， Carroll I A ， et al . Bucindolol decreases atrial fibrillation burden in patients with heart failure and the ADRB1 Arg389Arg genotype ［J/OL］. Circ Arrhythm Electrophysiol ， 2021 ， 14 （ 8 ）： e009591 . https：// pubmed.ncbi.nlm.nih.gov/34270905/ https://pubmed.ncbi.nlm.nih.gov/34270905/ .

Chow S C ， Shao J ， Wang H ， et al . Sample size calculations in clinical research ［M］. Boca Raton ： Chapman & Hall/CRC ， 2017 ： 50 .

郑筱萸 . 中药新药临床研究指导原则（试行）［M］. 北京：中国医药科技出版社， 2002 .

Hu Z ， Ding L ， Yao Y . Atrial fibrillation： mechanism and clinical management ［J］. Chin Med J （Engl）， 2023 ， 136 （ 22 ）： 2668 - 2676 .

陈佳凡，魏艺，贾博超，等 . 胡元会从“虚、瘀、痰、火”辨治持续性心房颤动经验［J］. 北京中医药， 2026 ， 45 （ 3 ）： 388 - 392 .

Doehner W ， Boriani G ， Potpara T ， et al . Atrial fibrillation burden in clinical practice， research， and technology deve-lopment： a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association ［J/OL］. Europace ， 2025 ， 27 （ 3 ）： euaf019 . https：//pubmed.ncbi.nlm.nih.gov/40073206/ https://pubmed.ncbi.nlm.nih.gov/40073206/ .

Singer D E ， Ziegler P D ， Koehler J L ， et al . Temporal association between episodes of atrial fibrillation and risk of ischemic stroke ［J］. JAMA Cardiol ， 2021 ， 6 （ 12 ）： 1364 - 1369 .

AlTurki A ， Essebag V . Atrial fibrillation burden： impact on stroke risk and beyond ［J/OL］. Medicina （Kaunas）， 2024 ， 60 （ 4 ）： 536 . https：//pubmed.ncbi.nlm.nih.gov/38674182/ https://pubmed.ncbi.nlm.nih.gov/38674182/ .

Mariani M V ， Recchioni T ， Pierucci N ， et al . Prognostic impact of spontaneous conversion to sinus rhythm in patients with symptomatic paroxysmal atrial fibrillation： a propensity-matched follow-up study ［J］. J Cardiovasc Electrophysiol ， 2025 ， 36 （ 12 ）： 3222 - 3230 .

Dong Y ， Zhai Z ， Wang J ， et al . Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation ［J/OL］. Sci Rep ， 2023 ， 13 （ 1 ）： 3140 . https：//pubmed.ncbi.nlm.nih.gov/36823222/ https://pubmed.ncbi.nlm.nih.gov/36823222/ .

König S ， Wohlrab L ， Leiner J ， et al . Patient perspectives on same-day discharge following catheter ablation for atrial fibrillation： results from a patient survey as part of the monocentric FAST AFA trial ［J/OL］. Europace ， 2023 ， 25 （ 9 ）： euad262 . https：//pubmed.ncbi.nlm.nih.gov/37656979/ https://pubmed.ncbi.nlm.nih.gov/37656979/ .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Shenlong Dingji Formula （参龙定悸方） on the Quality of Life in Patients with Paroxysmal Atrial Fibrillation of Qi-Yin Deficiency and Phlegm-Stasis Obstructing Collaterals Syndrome

Treatment of Paroxysmal Atrial Fibrillation by Deficiency-Excess Pattern Identification Based on “Palpitations Caused by Wind Pathogen”

The Effect of Modified Shugan Dingji Decoction （疏肝定悸汤） on the Occurrence of Endpoint Events in Patients with Paroxysmal Atrial Fibrillation of Liver Constraint and Qi Stagnation： A Retrospective Cohort Study

Clinical Observation on Yangyin Yixin Decoction Combined with Amiodarone for 31 Cases of Paroxysmal Atrial Fibrillation

Similarities and Differences between Myofascial Trigger Points and Sinew Knot：from the Perspective of the Channel Sinew Theory

Related Author

WANG Xian

DING Yukun

WANG Baofu

MA Liang

CHAI Ruoning

HU Yuanhui

LYU Meng

ZHU Xueping

Related Institution

Beijing University of Chinese Medicine

Dongzhimen Hospital，Beijing University of Chinese Medicine

Japan Friendship Hospital

Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine

Hospital of People's Liberation Army Navy

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Clinical Observation on Tianmeng Lingjiao Formula（天礞羚角方） as an Adjunctive Therapy for Paroxysmal Atrial Fibrillation with Phlegm-Heat Harassing the Interior Syndrome

DOI：10.13288/j.11-2166/r.2026.20.009

摘要

Abstract

关键词

Keywords

references